UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): December 7, 2011
PUMA BIOTECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 000-52811 | | 77-0683487 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
10940 Wilshire Blvd, Suite 600
Los Angeles, CA 90024
(Address of principal executive offices) (Zip Code)
(424) 248-6500
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 1.01 | Entry Into A Material Definitive Agreement. |
On December 7, 2011, Puma Biotechnology, Inc., a Delaware corporation (the “Company”), entered into an Office Lease (the “Lease”) with CA-10880 Wilshire Limited Partnership, a Delaware limited partnership, for approximately 13,254 rentable square feet of office space in the building located at 10880 Wilshire Boulevard, Los Angeles, California 90024 for use as the Company’s headquarters. The initial term of the Lease is for seven years and is expected to commence on or about December 19, 2011. The base rent will be approximately $44,400 per month during the first year and will increase each year during the initial term, up to approximately $53,000 per month during the seventh year. In addition, the Company has an option to extend the Lease for an additional five-year term, which would commence upon the expiration of the initial term. In the event the Company elects to extend the Lease, the minimum monthly rent payable for the additional term will be determined according to the then-prevailing market rate.
The foregoing summary of the Lease does not purport to be complete and is qualified in its entirety by reference to the full text of the Lease, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| | |
| 10.1 | | Office Lease by and between Puma Biotechnology, Inc. and CA-10880 Wilshire Limited Partnership, executed on December 7, 2011 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | |
| | PUMA BIOTECHNOLOGY, INC. |
| | |
| Date: December 13, 2011 | | By: | | /s/ Alan H. Auerbach |
| | | | Alan H. Auerbach |
| | | | Chief Executive Officer and President |
EXHIBIT INDEX
| | |
| Exhibit No. | | Description |
| |
| 10.1 | | Office Lease by and between Puma Biotechnology, Inc. and CA-10880 Wilshire Limited Partnership, executed on December 7, 2011 |
